Latest Breaking News On - Market equity offering program - Page 1 : comparemela.com

Bitfarms : INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 - Form 6-K

Bitfarms : INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 - Form 6-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Baie comeauUnited statesCanaan avalonJeffrey lucasNicolas bontaBitcoin blockchainQuebec incFinancial statements of the companyBackbone hosting solutionsBackbone hosting solutions paraguayForeign exchange ratesInternational accounting standards boardInternational accounting standardBlockfi lendingToronto stock exchangeCompany or bitfarms

NeuroSense CEO Provides Q3 2023 Update

Phase 2b ALS topline results expected December 2023 CAMBRIDGE, Mass., Oct. 17, 2023 /PRNewswire/ NeuroSense Therapeutics Ltd. , a company developing treatments for severe neurodegenerative.

United kingdomPrnewswire neurosense therapeutics ltdMarket equity offering programEuropean medicines agency opened officeExchange commission onExchange commissionNeurosense therapeutics ltdSense therapeuticsAlon ben noonSponsored study demonstrated primecOutstanding effectIchida stem cell labSouthern californiaEuropean medicines agencyOpened officeMedium sized enterprise

Neurosense Therapeutics (NRSN) CEO Issues Q3 2023 Update

Neurosense Therapeutics (NRSN) CEO Issues Q3 2023 Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Neurosense therapeutics ltdMarket equity offering programEuropean medicines agency opened officeNeurosense therapeuticsSponsored study demonstrated primecOutstanding effectIchida stem cell labSouthern californiaEuropean medicines agencyOpened officeMedium sized enterpriseAt the market equity offering program

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

$REVISED$ - $Adjusted Net Loss $ - $REVISED$ - $Adjusted EBITDA $50 - $100REVISED$100 - $150Adjusted Gross Margin % 36% - 39%REVISED39% - 42% Product/Service Level Revenue Anthrax MCM $200 -.

United statesRobertg kramerHaywood millerMatt hartwigReconciliation of researchExchange commissionCompany cantonDevelopment authorityCompany camdenProduct service level revenueEmergent biosolutions incBiomedical advanced researchDevelopment expensesDevelopment expenses to adjusted researchDrug administrationCompany bayview

O3 Mining Announces Corporate Updates

O3 Mining Announces Corporate Updates
goldseiten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from goldseiten.de Daily Mail and Mail on Sunday newspapers.

Community meetingMining incMarket equity offering programNational instrumentRegulation services providerCanaccord genuity corpCorporation the commonVenture exchangeOur responsible exploration programNews releaseProvides updateMeeting marbanMarban projectResponsible exploration programCommon sharesAll common shares